Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 656 | 95K | 301K | 2M | 663K |
| Gross Profit | -803K | 10K | -3M | -6M | -39K |
| Operating Income | -4M | -6M | -7M | -13M | -10M |
| EBITDA | -4M | -36M | -7M | -12M | -8M |
| Net Income | -4M | -37M | -6M | -12M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.35
+0.00% today
1Y Change
+25.36%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zelira Therapeutics Limited (ZLDAF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.35 and up 25.4% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -99.3%, EPS growth of +90.1%, a dividend yield of 0.0%. What stands out right now is revenue -99.3%, EPS +90.1%, free cash flow -11.8% with operating margin -663833.7% and ROIC 202.3%. Valuation already assumes a fairly strong business story at price/sales 9081.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZLDAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZLDAF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZLDAF Max Drawdown
-33.16%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZLDAF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$663.3K
-56.9% YoY
FY Net Income
-$8.5M
+28.4% YoY
Free Cash Flow
-$8.6M
+8.6% YoY
Revenue Growth
-99.3%
EPS Growth
+90.1%
Gross Margin
-122587.0%
Net Margin
-553873.6%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 656 | 95K | 301K | 2M | 663K |
| Gross Profit | -803K | 10K | -3M | -6M | -39K |
| Operating Income | -4M | -6M | -7M | -13M | -10M |
| EBITDA | -4M | -36M | -7M | -12M | -8M |
| Net Income | -4M | -37M | -6M | -12M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6K | 586K | 146K | 3M | 5M |
| Total Assets | 1M | 5M | 34M | 38M | 39M |
| Total Liabilities | 6M | 9M | 2M | 2M | 2M |
| Shareholder Equity | -4M | -5M | 32M | 35M | 38M |
| Total Debt | 2M | 6M | 438K | 501K | 551K |
| Net Debt | 2M | 5M | 292K | -2M | -4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+8.6% YoY
Capital Expenditures
0
Free Cash Flow
9M
+8.6% YoY
Key ratios
Gross Margin
-122587.0%
Operating Margin
-663833.7%
Net Margin
-553873.6%
ROE
56.4%
Debt / Equity
-0.48x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.